Biomarkers in the diagnosis of pleural diseases: a 2018 update
暂无分享,去创建一个
[1] Benjamin Solomon,et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[2] Jian-Xin Li,et al. Metabonomic classification and detection of small molecule biomarkers of malignant pleural effusions , 2012, Analytical and Bioanalytical Chemistry.
[3] T. Mafort,et al. Predominance of Th1 Immune Response in Pleural Effusion of Patients with Tuberculosis among Other Exudative Etiologies , 2019, Journal of Clinical Microbiology.
[4] Jing-jing Peng,et al. Metabolomic analysis based on 1H-nuclear magnetic resonance spectroscopy metabolic profiles in tuberculous, malignant and transudative pleural effusion , 2017, Molecular medicine reports.
[5] A. Aggarwal,et al. Diagnostic Performance of Xpert MTB/RIF in Tuberculous Pleural Effusion: Systematic Review and Meta-analysis , 2016, Journal of Clinical Microbiology.
[6] J. Porcel. Pleural fluid biomarkers: beyond the Light criteria. , 2013, Clinics in chest medicine.
[7] Yongwei Li,et al. Diagnostic and prognostic utilities of humoral fibulin-3 in malignant pleural mesothelioma: Evidence from a meta-analysis , 2017, Oncotarget.
[8] Kan Zhai,et al. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis , 2014, BMJ Open.
[9] B. Gu,et al. Diagnostic Accuracy of Natriuretic Peptides for Heart Failure in Patients with Pleural Effusion: A Systematic Review and Updated Meta-Analysis , 2015, PloS one.
[10] A. Aggarwal,et al. Interferon Gamma Release Assays for Diagnosis of Pleural Tuberculosis: a Systematic Review and Meta-Analysis , 2015, Journal of Clinical Microbiology.
[11] Anna Morley,et al. Investigating unilateral pleural effusions: the role of cytology , 2018, European Respiratory Journal.
[12] Kan Zhai,et al. Diagnostic accuracy of interleukin 27 for tuberculous pleural effusion: two prospective studies and one meta-analysis , 2017, Thorax.
[13] Clare Hooper,et al. Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010 , 2010, Thorax.
[14] J. M. Porcel,et al. Utility of CEA and CA 15-3 measurements in non-purulent pleural exudates in the diagnosis of malignancy: A single-center experience. , 2017, Archivos de bronconeumologia.
[15] J. M. Porcel,et al. Derrame pleural tuberculoso: características clínicas de 320 pacientes , 2019, Archivos de Bronconeumología.
[16] A. Fassina,et al. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: A route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers , 2017, Cancer cytopathology.
[17] J. M. Porcel. ¿Se debe realizar una biopsia pleural para el diagnóstico etiológico de los exudados? No , 2017 .
[18] Su Jin Lee,et al. Impact of Implementation of an Automated Liquid Culture System on Diagnosis of Tuberculous Pleurisy , 2015, Journal of Korean medical science.
[19] M. Tötsch,et al. The diagnostic role of BAP1 in serous effusions. , 2018, Human pathology.
[20] M. Mathieu,et al. Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site , 2018, Cancers.
[21] J. Huggins,et al. Can tuberculous pleural effusions be diagnosed by pleural fluid analysis alone? , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[22] R. Herbst,et al. Treatment of Advanced Non-Small Cell Lung Cancer in 2018. , 2018, JAMA oncology.
[23] J. M. Porcel,et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. , 2004, Chest.
[24] Chuifeng Fan,et al. Comparison of Epidermal Growth Factor Receptor Gene Mutations Identified Using Pleural Effusion and Primary Tumor Tissue Samples in Non–Small Cell Lung Cancer , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[25] J. M. Porcel,et al. Utilidad de la medición de CEA y CA 15-3 en los exudados pleurales no purulentos para diagnosticar malignidad: experiencia de un único centro , 2017 .
[26] E. Alkhalili,et al. Pleural Disease. , 2018, The New England journal of medicine.
[27] Charles L Daley,et al. Yield of sputum induction in the diagnosis of pleural tuberculosis. , 2003, American journal of respiratory and critical care medicine.
[28] Qing Zhang,et al. Comparison of laboratory testing methods for the diagnosis of tuberculous pleurisy in China , 2017, Scientific Reports.
[29] T. Brüning,et al. Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma , 2017, Disease markers.
[30] Yuan Yang,et al. Diagnostic Accuracy of Combinations of Tumor Markers for Malignant Pleural Effusion: An Updated Meta-Analysis , 2017, Respiration.
[31] C. Balañà,et al. 2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary , 2018, Clinical and Translational Oncology.
[32] R. Loddenkemper. [The diagnosis of pleural effusions]. , 1992, Deutsche medizinische Wochenschrift.
[33] Ziji Wei,et al. Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis. , 2014, International journal of clinical and experimental medicine.
[34] J. M. Porcel,et al. Diagnostic Accuracy of Pleural Fluid Adenosine Deaminase for Diagnosing Tuberculosis. Meta-analysis of Spanish Studies. , 2019, Archivos de bronconeumologia.
[35] J. M. Porcel,et al. Diagnostic performance of adenosine deaminase activity in pleural fluid: a single-center experience with over 2100 consecutive patients. , 2010, European journal of internal medicine.
[36] J. M. Porcel,et al. Diagnosis and Management of Pleural Transudates , 2017 .
[37] K. Azuma,et al. A Combined test using both cell sediment and supernatant cell‐free DNA in pleural effusion shows increased sensitivity in detecting activating EGFR mutation in lung cancer patients , 2018, Cytopathology : official journal of the British Society for Clinical Cytology.
[38] A. Velayati,et al. Impact of HIV infection on tuberculous pleural effusion , 2016, International journal of STD & AIDS.
[39] A. Rossi,et al. Treatment of advanced non small cell lung cancer. , 2011, Journal of thoracic disease.
[40] S. Bielsa,et al. Pleural effusions in acute decompensated heart failure: Prevalence and prognostic implications. , 2018, European journal of internal medicine.
[41] Jou-Wei Lin,et al. Revisiting tuberculous pleurisy: pleural fluid characteristics and diagnostic yield of mycobacterial culture in an endemic area , 2012, Thorax.
[42] J. M. Porcel,et al. Development and validation of a scoring system for the identification of pleural exudates of cardiac origin. , 2017, European journal of internal medicine.
[43] A. Gown,et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. , 2018, Archives of pathology & laboratory medicine.
[44] J. Foster,et al. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study , 2016, BMJ Open.
[45] S. Hong,et al. Loculated Tuberculous Pleural Effusion: Easily Identifiable and Clinically Useful Predictor of Positive Mycobacterial Culture from Pleural Fluid , 2016, Tuberculosis and respiratory diseases.
[46] B. Ortiz-Quintero,et al. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma , 2018, International journal of molecular sciences.
[47] Shaoqing Shi,et al. Accuracy of interleukin-27 assay for the diagnosis of tuberculous pleurisy , 2017, Medicine.
[48] T. Yusa. [Treatment of malignant pleural mesothelioma]. , 2007, Gan to kagaku ryoho. Cancer & chemotherapy.
[49] Concepción Martín,et al. Is it meaningful to use biochemical parameters to discriminate between transudative and exudative pleural effusions? , 2002, Chest.
[50] S. Bielsa,et al. Tuberculous Pleural Effusion: Clinical Characteristics of 320 Patients. , 2019, Archivos de bronconeumologia.
[51] W. Mooi,et al. Pulmonary hypertensive vasculopathy in parenchymal lung diseases and/or hypoxia , 2017, European Respiratory Review.
[52] J. M. Porcel,et al. Comparison of polymorphonuclear- and lymphocyte-rich tuberculous pleural effusions. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[53] S. Bielsa,et al. Biomarkers of heart failure in pleural fluid. , 2009, Chest.
[54] J. Soriano,et al. Recent epidemiological trends in tuberculous pleural effusion in Galicia, Spain. , 2012, European journal of internal medicine.
[55] J. M. Porcel,et al. Diagnosis and Management of Pleural Transudates. , 2017, Archivos de bronconeumologia.
[56] S. Cha,et al. Letter to the editor: Respective Contribution of Liquid and Solid Media to Mycobacterial Yields from Pleural Fluid in Tuberculous Pleural Effusion , 2015, Journal of Korean medical science.
[57] Huanzhong Shi,et al. Diagnostic value of interferon-gamma in tuberculous pleurisy: a metaanalysis. , 2007, Chest.
[58] Ling Xu,et al. Identifying tuberculous pleural effusion using artificial intelligence machine learning algorithms , 2019, Respiratory Research.
[59] Rufu Xu,et al. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis , 2016, Oncotarget.
[60] M. Slade,et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma , 2018, Thorax.
[61] Yangke Yu,et al. Diagnostic Accuracy of Interleukin-27 between Tuberculous Pleural Effusion and Malignant Pleural Effusion: A Meta-Analysis , 2018, Respiration.
[62] C. Bolliger,et al. The yield of different pleural fluid volumes for Mycobacterium tuberculosis culture , 2012, Thorax.
[63] Examination of cytological smears and cell blocks of pleural fluid: Complementary diagnostic value for malignant effusions. , 2017, Revista clinica espanola.
[64] Renato Martins,et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[65] K. Rabe,et al. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. , 2017, The New England journal of medicine.
[66] J. M. Porcel,et al. Identifying Thoracic Malignancies Through Pleural Fluid Biomarkers , 2016, Medicine.
[67] Huanzhong Shi,et al. Diagnostic Value of Interferon-γ in Tuberculous Pleurisy: A Metaanalysis , 2007 .
[68] F. Galateau-Sallé,et al. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet? , 2016, Archives of pathology & laboratory medicine.
[69] L. Bubendorf,et al. Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens , 2017, European Respiratory Review.
[70] S. Roy-Chowdhuri. Advances in Molecular Testing Techniques in Cytologic Specimens. , 2018, Surgical pathology clinics.
[71] S. Armato,et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] R. Molina,et al. Evaluation of two strategies for the interpretation of tumour markers in pleural effusions , 2017, Respiratory Research.
[73] Hayoung Choi,et al. Clinical and Laboratory Differences between Lymphocyte- and Neutrophil-Predominant Pleural Tuberculosis , 2016, PloS one.
[74] N. Maskell,et al. ERS/EACTS statement on the management of malignant pleural effusions , 2018, European Respiratory Journal.
[75] J. Porcel. Advances in the diagnosis of tuberculous pleuritis. , 2016, Annals of translational medicine.
[76] J. M. Porcel,et al. Identifying transudates misclassified by Light's criteria , 2013, Current opinion in pulmonary medicine.
[77] J. Park,et al. Does repeated pleural culture increase the diagnostic yield of Mycobacterium tuberculosis from tuberculous pleural effusion in HIV-negative individuals? , 2017, PloS one.
[78] G. Pescetti,et al. [Pleural effusions]. , 1965, Aggiornamenti clinicoterapeutici.
[79] J. M. Porcel,et al. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. , 2014, Archivos de bronconeumologia.
[80] S. Monaco,et al. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples , 2018, Advances in anatomic pathology.
[81] J. M. Porcel,et al. Etiología del derrame pleural: análisis de más de 3.000 toracocentesis consecutivas , 2014 .
[82] J. M. Porcel. The case against performing pleural biopsies for the aetiological diagnosis of exudates , 2017 .
[83] J. Park,et al. Different characteristics of tuberculous pleural effusion according to pleural fluid cellular predominance and loculation. , 2016, Journal of thoracic disease.
[84] J. Creaney,et al. Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment , 2017, Chest.